SlideShare a Scribd company logo
1 of 72
Chronic Kidney Disease
in Elderly
Adnan Naseer, M.D.
Assistant Professor of Medicine
Division of Nephrology
University of Tennessee, Memphis
Outline
Epidemiology of chronic kidney disease in
elderly
Aging and kidney
Outcomes in chronic kidney disease and
end stage renal disease in elderly
Management strategies in elderly with
chronic kidney disease
Palliative care and chronic kidney disease
The Graying of America
According to US Census Bureau projections, the
elderly population will more than double between
2000 and 2030, growing from 35 million to over 70
million.
Much of this growth is attributed to the "baby
boom" generation which will enter their elderly
years between 2010 and 2030.
Source of data: U.S. Census Bureau, “65+ in the United States: 2005,” December 2005.
U.S. Population Pyramids
Source of charts: U.S. Census Bureau, “65+ in the United States: 2005,” December 2005.
2000 2020 2040
The Oldest Old
The "oldest old" – those aged 85 and over – are
the most rapidly growing elderly age group.
The oldest old represented 12.1% of the elderly
population in 2000 and 1.5% of the total
population. In 2050, they are projected to be
24% of elderly Americans and 5% of all
Americans.
Increases in the Oldest Old
U.S. Population Aged 85+ (in millions)
0.2 0.3 0.4 0.6 0.9 1.5 2.2
3.1
4.2
6.1
7.3
9.6
15.4
20.9
0.2
0.1
1900
1910
1920
1930
1940
1950
1960
1970
1980
1990
2000
2010
2020
2030
2040
2050
Sources of data: U.S. Census Bureau, “65+ in the United States: 2005,” December 2005; U.S. Census
Bureau, U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin, 2004.
In United States,
people >65 years of age
have an average of
3.5 chronic illnesses
per person
Chronic Health Problems
Percent of 65+ with selected conditions, 2003-2004
23.8%
10.1%
37.2%
48.1%
19.5%
42.9%
18.1%
27.7%
54.7%
8.5%
15.1%
55%
0
10
20
30
40
50
60
Heart
Disease
Hyper-
tension
Stroke Cancer Diabetes Arthritis
Males Females
Source of data: U.S. Census Bureau, Older Americans Update 2006: Key Indicators of Well-Being, May 2006.
Chronic Kidney Disease
an Epidemic
Distribution of NHANES 1999–2006
participants, by eGFR & method used to
estimate GFR
USRDS 2010 ADR
Prevalence of comorbidity in NHANES
1999–2006 participants, by eGFR
& method used to estimate GFR
USRDS 2010 ADR
Incident
counts
&
adjusted
rates,
by age
Incident ESRD patients; rates
adjusted for gender & race.
USRDS 2010 ADR
50% of Americans over 69 have CKD
Prevalence of Moderate CKD by Age
Group (NHANES)
27%
37%
Coresh et al., JAMA 2007;298(17):2038-2047
Prevalence of CKD in U.S.
2000 Census
Thus, about 16 million Americans have a GFR less
than 60 mL/min/1.73 m2. Plus 10 million more have a
GFR over 60 but have persistent albuminuria.
Coresh, et al., 2007
GFR
(mL/min/1.73 m2)
59-30 29-15
Number of People 15.5 Million 0.7 Million
Prevalence of Low eGFR by Age Group Among US Veterans
Ann M. O’Hare et al JASN 2007
Why Chronic Kidney Disease
is So Prevalent in Elderly?
Age related changes in GFR
– Increasing longevity
Epidemic of DM, HTN, CVD and Obesity
Automatic reporting of eGFR
– Increasing awareness
Kidney and Aging
Aging Related Changes
Anatomic Changes
– Loss of renal mass; 10% reduction per decade. Wt of
kidney 400 g at 4th decade, 200 g at 8th decade.
– Glomerulosclerosis, predominantly cortical nephrons.
– Tubulointerstitial fibrosis.
Renal blood flow
– Progressive reduction in renal plasma flow from 600
ml/min to 300 ml/min by age 80.
Effect of Age on eGFR
The “normal” eGFR is age-related
In normal “healthy” individuals, the eGFR will
fall by one percent for every year after 40
years of age
An 80 year old man will have an expected
eGFR of 50-60 ml/min
GFR Does Not Always
Decline With Age
Baltimore Longitudinal Study
of Aging
1958-1981
446 volunteers age 22 to 97 years old
Observed decline of 8.0 ml/min per 1.73
m²/decade of life.
One third of subjects did not have decline
in GFR.
Lindeman RD et al., J Am Geriatr Soc 1985;33:278-285.
Progression and
Outcomes in CKD
26.3
0.5 Stage 5
Millions of individuals
Stages 1-4
CKD Epidemic
Adjusted Risk of Mortality for
eGFR <60 in adults >65 years
CKD Prognosis Consortium, Lancet, 2010
Adjusted for ACR Adjusted for Dipstick Protein
Reference: eGFR 95 ml/min
CKD leads to CVD
1.0
1.4
2.0
2.8
3.4
0.0
1.0
2.0
3.0
4.0
≥ 60 45-59 30-44 15-29 < 15
Adjusted
Hazard Ratio
for CVD Events
Go A, et al. NEJM 2004;351:1296-1305
eGFR ml/min/1.73 m2
Go A, et al. NEJM 2004;351:1296-1305
CKD and Risk of Death
Age affects Outcomes in CKD
All patients with eGFR <60 in the year following
October 1, 2000 who had an additional eGFR
<60 in the previous 3 months
Creatinine and outcomes were followed for up to
4 years
209,622 veterans with stage 3-5 CKD
Mean age 73, 47% over 75
O’Hare , A. M. et al. J Am Soc Nephrol 2007;18:2758-2765
Absolute risk of ESRD decreases with
age among patients with similar level of
eGFR
Copyright ©2007 American Society of Nephrology
O'Hare, A. M. et al. J Am Soc Nephrol 2007;18:2758-2765
Figure 2. Baseline eGFR threshold below which risk for ESRD exceeded risk for death for each age group
“Progression of kidney dysfunction in the
community-dwelling elderly”
All subjects > 66 years old, two years of follow-up
1% reached ESRD, of which 93 % came from group with eGFR < 30
Hemmelgarn et al, KI 2006
Cont’d
Risk Factors for Progression of CKD
Diabetes Mellitus
Hypertension
Proteinuria
Advanced CKD (eGFR <30 ml/min)
Male gender
Minority race
Which individuals with
abnormal eGFR should we
worry about?
Those with very poor kidney function for age
Those with deteriorating kidney function
Those who may have reversible/treatable cause
(unexplained proteinuria/hematuria)
Those with functional consequences of CKD
(anemia, renal bone disease, persistent
hyperkalemia)
Management of CKD
Few randomized control trials to support specific
management strategies
Most trials excluded or very few patients >70 years old
Results of RCTs may not be generalizable to older
patients
– Differences in progression of CKD, development of ESRD and
death
– Greater burden of co-morbidities, dementia, frailty
Current guidelines advocate “Age Neutral” approach
Care of elderly CKD patients should be individualized
and integrated with patient preferences
Therapeutic Intervention in
CKD
Advice to reduce cardiovascular risk
(weight, smoking, diet, lipids etc)
Tight BP control (more stringent target if
Proteinuria)
ACE-inhibitors & ARBs (check eGFR
and K+ 7-10 days later)
Anemia management
Bone disease
ESRD in Elderly
Frequent co-morbidities: CVD, malnutrition
Disabilities: physical, cognitive, hearing,
visual
Nursing home care
Higher mortality: mean survival for patients
older than 75 years on RRT is 31 months
Cumulative survival in two groups of hemodialysis patients: A represents
patients between 50 and 60 years old. B represents patients above 75
years old. January 1996 to December 2000.
Patients 50-60 yrs
Survival rates at 1
and 3 years 93%
and 74%
Survival in ESRD Patients Over 75 Years Old
Patients >75 yrs
Survival rates at 1
and 3 years 80%
and 45%
Leblanc et al. Am J Nephrol. 2003 Mar-Apr;23(2):71-7
Changes in Survival Among
Elderly ESRD Patients
CMAJ October 2007, Jassal et al, CORR data
Dialysis or not?
A comparative survival study of patients over 75
years with chronic kidney disease stage 5
Retrospective analysis of 129 patients , Follow-up ~570 days
Murtagh et al, Nephrology, Dialysis Transplantation 2007
Survival With and Without Dialysis
Murtagh et al, Nephrology, Dialysis Transplantation 2007
Kaplan-Meier survival curves in high co-morbidity only patients
Murtagh et al, Nephrology, Dialysis Transplantation 2007
Estimating Prognosis in
ESRD Patients
Mortality Risk Factors in ESRD
Age
Malnutrition
Comorbidities
Functional status
Age as Risk Factor for Death
3-4% increase in death rate for each one year
increment in age beginning at age 18.
2011 USRDS Annual Data Report
Malnutrition and ESRD
Relative risk of mortality and quartiles of serum albumin.
Adjusted for baseline albumin (A), ∆albumin (B)
Pifer et al. DOPPS Kidney Int 2002;62(6):2238-45
Functional Status and ESRD
Poor functional status is highly predictive of early
death (RR 1.5 to 3.0)
Measures of functional status
– Ability to ambulate (yes/no)
– Karnofsky scale
– Activities of daily living
Inability to transfer and falls are indicators of poor
prognosis
Comorbiditiy and ESRD
DM, CHF, CAD, PVD, COPD, malignancy
Comorbidity scores
– Charlson Comorbidity Index
– ESRD (Modified Charlson) Comorbidity Index
Adapting Charlson Comorbidity
Index for ESRD Patients
(A) ESRD Comorbidity
Index score
(B) Charlson Comorbidity
Index score
Kaplan-Meier Survival
Plots
Hemmelgarn et al. AJKD, 42(1), 2003: 125-32
The “Surprise” Question
“Would I be surprised if this patient died
in the next 12 months?”
Moss et al. Clin J Am Soc Nephrol; 3: 1379-84, 2008
Predicting Who Will Die Within
First Year on Dialysis
– An integrated mathematical prognostic model
takes into account:
– Clinician’s estimate of prognosis
– Laboratory values
– Comorbidities
– Functional status
HD Mortality Predictor
Mathematical model for estimating patient
survival at 6 months using
– The “Surprise” question
– Serum albumin
– Age
– Presence or absence of dementia and PVD
http://touchcalc.com/calculators/sq
Cohen et al, Clin J Am Soc Nephrol 2010; 5(1):72-9
Palliative Care
Definition
Palliative care is comprehensive,
interdisciplinary care of patients and
families facing a chronic or terminal
illness focusing primarily on comfort and
support.
Billings JA. Palliative Care. Recent Advances. BMJ 2000:321:555-558.
Aspects of Palliative Care
Pain and symptom management
Advance care planning
–DNR
–Advance Directives
Psychosocial and spiritual support
When is Palliative Care Needed?
Around the decision to stop dialysis
At the onset of conservative management
When symptoms from co-morbid conditions
are severe
At times of crisis e.g. new diagnosis of
malignancy, or acute severe symptoms
Patients who develop renal failure as a
consequence of other life threatening
conditions or its treatment e.g. cancer
Criteria for Withholding Dialysis
Patient or surrogate wishes
Profound neurologic impairment
– Persistent vegetative state, stroke, dementia
Non-renal terminal condition
– Malignancy, end-stage liver, heart, lungs
Medical condition that precludes process of
dialysis
Age, per se, is not a criterion to withhold dialysis
Symptoms During Last 24 Hours
N=79
Symptom % present
Pain 42
Agitation 30
Myoclonus/twitching 28
Dyspnea/agonal breathing 25
Fever 20
Diarrhea 14
Dysphagia 14
Nausea 13
Cohen et al. AJKD, 2000;36:140-144
RPA/ASN Statement
on Quality Care at the End of Life
Recommendations
1. All members of the renal health care team including
nephrologists, nephrology nurses, nephrology social
workers, and renal dietitians should obtain education
and skills in the principles of palliative care to ensure
that ESRD patients and families receive
multidimensional, compassionate, and competent care
at the end of life.
RPA/ASN Statement on Quality Care
at the End of Life
RPA/ASN Statement on Quality Care
at the End of Life
2. In responding to an ESRD patient/surrogate decision
to forgo dialysis, the nephrologist is obligated to
determine, if possible, why the patient/surrogate has
decided to forgo dialysis … Once the nephrologist is
satisfied that the patient’s decision to forgo dialysis is
informed and uncoerced, the nephrologist should
respect the wishes of the patient/surrogate.
3. After a decision is made to forgo dialysis, the renal
team should refer the patient to a hospice or adopt
a palliative care approach to patient care. In either
case, the nephrologist and other members of the
renal team should remain active in the patient’s
care to maintain continuity of relationships and
treatment.
RPA/ASN Statement on Quality Care
at the End of Life
4. Nephrologists and other members of the renal
team should obtain education and skills in advance
care planning so that they are comfortable
addressing end-of-life issues with their patients.
RPA/ASN Statement on Quality Care
at the End of Life
Exposure to Palliative Care
Geriatrics Critical
Care
Nephrology
Completed a Rotation
Focused on Palliative Care
71% 2% 1%
Had Contact with Palliative
Care Specialist
80% 46% 45%
Quality of teaching with
respect to end-of-life care
rated ‘very good’ or
‘excellent’
53% 34% 15%
Holley et al. Am J Kidney Dis 42(4):813-820, 2003.
Amount of Training to Manage a
Dying Patient
0%
10%
20%
30%
40%
50%
60%
0-3 4-7 8-10
0=No Training 10=A Lot of Training
Geriatrics
Pulmonary/ Critical Care
Nephrology
Clinical Scenario
Age 85
eGFR 30
Congestive heart failure, unable to
manage stairs
No proteinuria
Cont’d
This patient is likely to have a
cardiorenal syndrome
Evidence of progression?
– if not, conservative management
– if so, is there any prospect of reversibility
(in this case probably not) or would the
patient tolerate/ benefit from renal
replacement therapy (in this case probably
not)
Palliative care pathway
Summary
Assess risk for CKD progression
– Serial eGFR
– Proteinuria and other risk factors
Assess CV risk
– As per high risk group guidelines
Assess for CKD complications
– Anemia
– Bone disease
– Malnutrition
Assess for renal replacement VS Non-dialytic therapy
Assess for palliative care

More Related Content

What's hot

Diabetic Nephropathy
Diabetic NephropathyDiabetic Nephropathy
Diabetic Nephropathy
Joel Topf
 

What's hot (20)

Diabetes + Kidney disease
Diabetes + Kidney diseaseDiabetes + Kidney disease
Diabetes + Kidney disease
 
FIDELIO-DKD Trial
FIDELIO-DKD TrialFIDELIO-DKD Trial
FIDELIO-DKD Trial
 
Chronic Kidney Disease Update 2019
Chronic Kidney Disease Update 2019Chronic Kidney Disease Update 2019
Chronic Kidney Disease Update 2019
 
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. GawadElectrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
 
Anemia wi
Anemia wiAnemia wi
Anemia wi
 
Management of Diabetes in Hemodialysis Patients
Management of Diabetes in Hemodialysis PatientsManagement of Diabetes in Hemodialysis Patients
Management of Diabetes in Hemodialysis Patients
 
ESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. GawadESAs Therapy: Friend or Foe? - Dr. Gawad
ESAs Therapy: Friend or Foe? - Dr. Gawad
 
Diabetic Nephropathy
Diabetic NephropathyDiabetic Nephropathy
Diabetic Nephropathy
 
Acute Kidney Injury Management (Volume Replacement) - Dr. Gawad
Acute Kidney Injury Management (Volume Replacement) - Dr. Gawad Acute Kidney Injury Management (Volume Replacement) - Dr. Gawad
Acute Kidney Injury Management (Volume Replacement) - Dr. Gawad
 
EMPA-KIDNEY.pptx
EMPA-KIDNEY.pptxEMPA-KIDNEY.pptx
EMPA-KIDNEY.pptx
 
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. GawadIs It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
 
Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...
Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...
Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...
 
The Aging Kidney - Why it is more vulnerable for injury? - Applied clinical p...
The Aging Kidney - Why it is more vulnerable for injury? - Applied clinical p...The Aging Kidney - Why it is more vulnerable for injury? - Applied clinical p...
The Aging Kidney - Why it is more vulnerable for injury? - Applied clinical p...
 
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. GawadDrug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
Drug Dosing and Prescription in CKD & ESRD (Updates - Highlights) - Dr. Gawad
 
Hypertension in Chronic Kidney Disease
Hypertension in Chronic Kidney DiseaseHypertension in Chronic Kidney Disease
Hypertension in Chronic Kidney Disease
 
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadInsights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. Gawad
 
Ckd mbd
Ckd mbdCkd mbd
Ckd mbd
 
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBaryCardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
Cardiovascular complications in CKD - Dr. Mohamed Mamdouh AbdAlBary
 
Is it Hepatorenal Syndrome? - Dr. Gawad
Is it Hepatorenal Syndrome? - Dr. GawadIs it Hepatorenal Syndrome? - Dr. Gawad
Is it Hepatorenal Syndrome? - Dr. Gawad
 
Membranous Nephropathy - Dr. Gawad
Membranous Nephropathy - Dr. GawadMembranous Nephropathy - Dr. Gawad
Membranous Nephropathy - Dr. Gawad
 

Similar to chronic-kidney-disease-elderly.pptx

MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
European School of Oncology
 

Similar to chronic-kidney-disease-elderly.pptx (20)

Ckd 2016 100 1
Ckd 2016 100 1Ckd 2016 100 1
Ckd 2016 100 1
 
Diabetes lecture
Diabetes lectureDiabetes lecture
Diabetes lecture
 
59010-128_Slides.pptx
59010-128_Slides.pptx59010-128_Slides.pptx
59010-128_Slides.pptx
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...
 
Lifestyle Related Kidney Diseases
Lifestyle Related Kidney DiseasesLifestyle Related Kidney Diseases
Lifestyle Related Kidney Diseases
 
Obesity paradox
Obesity paradoxObesity paradox
Obesity paradox
 
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
MON 2011 - Slide 17 - L. Repetto - Spotlight session - Cancer in the older pe...
 
Coronary heart disease - epidemiology
Coronary heart disease - epidemiologyCoronary heart disease - epidemiology
Coronary heart disease - epidemiology
 
Chronic Kidney Disease Challenges and New Solutions
Chronic Kidney Disease Challenges and New SolutionsChronic Kidney Disease Challenges and New Solutions
Chronic Kidney Disease Challenges and New Solutions
 
Racial disparaties in Chronic Kidney Diseases
Racial disparaties in Chronic Kidney DiseasesRacial disparaties in Chronic Kidney Diseases
Racial disparaties in Chronic Kidney Diseases
 
ภาวะแทรกซ้อนทางไตในผู้ป่วยเบาหวาน
ภาวะแทรกซ้อนทางไตในผู้ป่วยเบาหวานภาวะแทรกซ้อนทางไตในผู้ป่วยเบาหวาน
ภาวะแทรกซ้อนทางไตในผู้ป่วยเบาหวาน
 
CVD Risk Managemnt- Focus on HTN & Dys.pdf
CVD Risk Managemnt- Focus on HTN & Dys.pdfCVD Risk Managemnt- Focus on HTN & Dys.pdf
CVD Risk Managemnt- Focus on HTN & Dys.pdf
 
Outpatient Management of CKD Patients
Outpatient Management of CKD PatientsOutpatient Management of CKD Patients
Outpatient Management of CKD Patients
 
Ndei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes EpidemiologyNdei Cardiovascular Disease In Diabetes Epidemiology
Ndei Cardiovascular Disease In Diabetes Epidemiology
 
HCM SCD.pptx
HCM SCD.pptxHCM SCD.pptx
HCM SCD.pptx
 
Antiprotenuric Antihypertensives.pptx
Antiprotenuric Antihypertensives.pptxAntiprotenuric Antihypertensives.pptx
Antiprotenuric Antihypertensives.pptx
 
Sarnak2019
Sarnak2019Sarnak2019
Sarnak2019
 
Primary care screening tests in adults geriatrics
Primary care screening tests in adults  geriatricsPrimary care screening tests in adults  geriatrics
Primary care screening tests in adults geriatrics
 
Overweight and obesity in adults health consequences
Overweight and obesity in adults health consequencesOverweight and obesity in adults health consequences
Overweight and obesity in adults health consequences
 
Cardiovascular problems in Elderly
Cardiovascular problems in ElderlyCardiovascular problems in Elderly
Cardiovascular problems in Elderly
 

More from Huda693686 (8)

Approach_to_floppy_infant__1_.pptx
Approach_to_floppy_infant__1_.pptxApproach_to_floppy_infant__1_.pptx
Approach_to_floppy_infant__1_.pptx
 
Dengue.pptx
Dengue.pptxDengue.pptx
Dengue.pptx
 
DOC-20230315-WA0093..pptx
DOC-20230315-WA0093..pptxDOC-20230315-WA0093..pptx
DOC-20230315-WA0093..pptx
 
Systemic-Hypertension-and-Renal-transplantation-in-ARPKD.ppt
Systemic-Hypertension-and-Renal-transplantation-in-ARPKD.pptSystemic-Hypertension-and-Renal-transplantation-in-ARPKD.ppt
Systemic-Hypertension-and-Renal-transplantation-in-ARPKD.ppt
 
Radiology-I.pptx
Radiology-I.pptxRadiology-I.pptx
Radiology-I.pptx
 
CASE PRESENTATION BY DR ALI SHER_1.pptx
CASE PRESENTATION BY DR ALI SHER_1.pptxCASE PRESENTATION BY DR ALI SHER_1.pptx
CASE PRESENTATION BY DR ALI SHER_1.pptx
 
OMICRON BASICS.pdf
OMICRON BASICS.pdfOMICRON BASICS.pdf
OMICRON BASICS.pdf
 
5- Measuring a Malnourished Child.pptx
5- Measuring a Malnourished Child.pptx5- Measuring a Malnourished Child.pptx
5- Measuring a Malnourished Child.pptx
 

Recently uploaded

The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPSSpellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
AnaAcapella
 

Recently uploaded (20)

Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
AIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.pptAIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.ppt
 
Basic Intentional Injuries Health Education
Basic Intentional Injuries Health EducationBasic Intentional Injuries Health Education
Basic Intentional Injuries Health Education
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPSSpellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
latest AZ-104 Exam Questions and Answers
latest AZ-104 Exam Questions and Answerslatest AZ-104 Exam Questions and Answers
latest AZ-104 Exam Questions and Answers
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 

chronic-kidney-disease-elderly.pptx

  • 1. Chronic Kidney Disease in Elderly Adnan Naseer, M.D. Assistant Professor of Medicine Division of Nephrology University of Tennessee, Memphis
  • 2. Outline Epidemiology of chronic kidney disease in elderly Aging and kidney Outcomes in chronic kidney disease and end stage renal disease in elderly Management strategies in elderly with chronic kidney disease Palliative care and chronic kidney disease
  • 3. The Graying of America According to US Census Bureau projections, the elderly population will more than double between 2000 and 2030, growing from 35 million to over 70 million. Much of this growth is attributed to the "baby boom" generation which will enter their elderly years between 2010 and 2030. Source of data: U.S. Census Bureau, “65+ in the United States: 2005,” December 2005.
  • 4. U.S. Population Pyramids Source of charts: U.S. Census Bureau, “65+ in the United States: 2005,” December 2005. 2000 2020 2040
  • 5. The Oldest Old The "oldest old" – those aged 85 and over – are the most rapidly growing elderly age group. The oldest old represented 12.1% of the elderly population in 2000 and 1.5% of the total population. In 2050, they are projected to be 24% of elderly Americans and 5% of all Americans.
  • 6. Increases in the Oldest Old U.S. Population Aged 85+ (in millions) 0.2 0.3 0.4 0.6 0.9 1.5 2.2 3.1 4.2 6.1 7.3 9.6 15.4 20.9 0.2 0.1 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 Sources of data: U.S. Census Bureau, “65+ in the United States: 2005,” December 2005; U.S. Census Bureau, U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin, 2004.
  • 7. In United States, people >65 years of age have an average of 3.5 chronic illnesses per person
  • 8. Chronic Health Problems Percent of 65+ with selected conditions, 2003-2004 23.8% 10.1% 37.2% 48.1% 19.5% 42.9% 18.1% 27.7% 54.7% 8.5% 15.1% 55% 0 10 20 30 40 50 60 Heart Disease Hyper- tension Stroke Cancer Diabetes Arthritis Males Females Source of data: U.S. Census Bureau, Older Americans Update 2006: Key Indicators of Well-Being, May 2006.
  • 10. Distribution of NHANES 1999–2006 participants, by eGFR & method used to estimate GFR USRDS 2010 ADR
  • 11. Prevalence of comorbidity in NHANES 1999–2006 participants, by eGFR & method used to estimate GFR USRDS 2010 ADR
  • 12. Incident counts & adjusted rates, by age Incident ESRD patients; rates adjusted for gender & race. USRDS 2010 ADR
  • 13. 50% of Americans over 69 have CKD
  • 14. Prevalence of Moderate CKD by Age Group (NHANES) 27% 37% Coresh et al., JAMA 2007;298(17):2038-2047
  • 15. Prevalence of CKD in U.S. 2000 Census Thus, about 16 million Americans have a GFR less than 60 mL/min/1.73 m2. Plus 10 million more have a GFR over 60 but have persistent albuminuria. Coresh, et al., 2007 GFR (mL/min/1.73 m2) 59-30 29-15 Number of People 15.5 Million 0.7 Million
  • 16. Prevalence of Low eGFR by Age Group Among US Veterans Ann M. O’Hare et al JASN 2007
  • 17. Why Chronic Kidney Disease is So Prevalent in Elderly?
  • 18. Age related changes in GFR – Increasing longevity Epidemic of DM, HTN, CVD and Obesity Automatic reporting of eGFR – Increasing awareness
  • 20. Aging Related Changes Anatomic Changes – Loss of renal mass; 10% reduction per decade. Wt of kidney 400 g at 4th decade, 200 g at 8th decade. – Glomerulosclerosis, predominantly cortical nephrons. – Tubulointerstitial fibrosis. Renal blood flow – Progressive reduction in renal plasma flow from 600 ml/min to 300 ml/min by age 80.
  • 21.
  • 22. Effect of Age on eGFR The “normal” eGFR is age-related In normal “healthy” individuals, the eGFR will fall by one percent for every year after 40 years of age An 80 year old man will have an expected eGFR of 50-60 ml/min
  • 23.
  • 24. GFR Does Not Always Decline With Age
  • 25. Baltimore Longitudinal Study of Aging 1958-1981 446 volunteers age 22 to 97 years old Observed decline of 8.0 ml/min per 1.73 m²/decade of life. One third of subjects did not have decline in GFR. Lindeman RD et al., J Am Geriatr Soc 1985;33:278-285.
  • 27. 26.3 0.5 Stage 5 Millions of individuals Stages 1-4 CKD Epidemic
  • 28. Adjusted Risk of Mortality for eGFR <60 in adults >65 years CKD Prognosis Consortium, Lancet, 2010 Adjusted for ACR Adjusted for Dipstick Protein Reference: eGFR 95 ml/min
  • 29. CKD leads to CVD 1.0 1.4 2.0 2.8 3.4 0.0 1.0 2.0 3.0 4.0 ≥ 60 45-59 30-44 15-29 < 15 Adjusted Hazard Ratio for CVD Events Go A, et al. NEJM 2004;351:1296-1305 eGFR ml/min/1.73 m2
  • 30. Go A, et al. NEJM 2004;351:1296-1305 CKD and Risk of Death
  • 31.
  • 32. Age affects Outcomes in CKD All patients with eGFR <60 in the year following October 1, 2000 who had an additional eGFR <60 in the previous 3 months Creatinine and outcomes were followed for up to 4 years 209,622 veterans with stage 3-5 CKD Mean age 73, 47% over 75 O’Hare , A. M. et al. J Am Soc Nephrol 2007;18:2758-2765
  • 33. Absolute risk of ESRD decreases with age among patients with similar level of eGFR Copyright ©2007 American Society of Nephrology O'Hare, A. M. et al. J Am Soc Nephrol 2007;18:2758-2765 Figure 2. Baseline eGFR threshold below which risk for ESRD exceeded risk for death for each age group
  • 34. “Progression of kidney dysfunction in the community-dwelling elderly” All subjects > 66 years old, two years of follow-up 1% reached ESRD, of which 93 % came from group with eGFR < 30 Hemmelgarn et al, KI 2006
  • 36. Risk Factors for Progression of CKD Diabetes Mellitus Hypertension Proteinuria Advanced CKD (eGFR <30 ml/min) Male gender Minority race
  • 37. Which individuals with abnormal eGFR should we worry about? Those with very poor kidney function for age Those with deteriorating kidney function Those who may have reversible/treatable cause (unexplained proteinuria/hematuria) Those with functional consequences of CKD (anemia, renal bone disease, persistent hyperkalemia)
  • 38. Management of CKD Few randomized control trials to support specific management strategies Most trials excluded or very few patients >70 years old Results of RCTs may not be generalizable to older patients – Differences in progression of CKD, development of ESRD and death – Greater burden of co-morbidities, dementia, frailty Current guidelines advocate “Age Neutral” approach Care of elderly CKD patients should be individualized and integrated with patient preferences
  • 39. Therapeutic Intervention in CKD Advice to reduce cardiovascular risk (weight, smoking, diet, lipids etc) Tight BP control (more stringent target if Proteinuria) ACE-inhibitors & ARBs (check eGFR and K+ 7-10 days later) Anemia management Bone disease
  • 40. ESRD in Elderly Frequent co-morbidities: CVD, malnutrition Disabilities: physical, cognitive, hearing, visual Nursing home care Higher mortality: mean survival for patients older than 75 years on RRT is 31 months
  • 41. Cumulative survival in two groups of hemodialysis patients: A represents patients between 50 and 60 years old. B represents patients above 75 years old. January 1996 to December 2000. Patients 50-60 yrs Survival rates at 1 and 3 years 93% and 74% Survival in ESRD Patients Over 75 Years Old Patients >75 yrs Survival rates at 1 and 3 years 80% and 45% Leblanc et al. Am J Nephrol. 2003 Mar-Apr;23(2):71-7
  • 42. Changes in Survival Among Elderly ESRD Patients CMAJ October 2007, Jassal et al, CORR data
  • 43. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5 Retrospective analysis of 129 patients , Follow-up ~570 days Murtagh et al, Nephrology, Dialysis Transplantation 2007
  • 44. Survival With and Without Dialysis Murtagh et al, Nephrology, Dialysis Transplantation 2007
  • 45. Kaplan-Meier survival curves in high co-morbidity only patients Murtagh et al, Nephrology, Dialysis Transplantation 2007
  • 47. Mortality Risk Factors in ESRD Age Malnutrition Comorbidities Functional status
  • 48. Age as Risk Factor for Death 3-4% increase in death rate for each one year increment in age beginning at age 18. 2011 USRDS Annual Data Report
  • 49. Malnutrition and ESRD Relative risk of mortality and quartiles of serum albumin. Adjusted for baseline albumin (A), ∆albumin (B) Pifer et al. DOPPS Kidney Int 2002;62(6):2238-45
  • 50. Functional Status and ESRD Poor functional status is highly predictive of early death (RR 1.5 to 3.0) Measures of functional status – Ability to ambulate (yes/no) – Karnofsky scale – Activities of daily living Inability to transfer and falls are indicators of poor prognosis
  • 51. Comorbiditiy and ESRD DM, CHF, CAD, PVD, COPD, malignancy Comorbidity scores – Charlson Comorbidity Index – ESRD (Modified Charlson) Comorbidity Index
  • 52. Adapting Charlson Comorbidity Index for ESRD Patients (A) ESRD Comorbidity Index score (B) Charlson Comorbidity Index score Kaplan-Meier Survival Plots Hemmelgarn et al. AJKD, 42(1), 2003: 125-32
  • 53. The “Surprise” Question “Would I be surprised if this patient died in the next 12 months?” Moss et al. Clin J Am Soc Nephrol; 3: 1379-84, 2008
  • 54. Predicting Who Will Die Within First Year on Dialysis – An integrated mathematical prognostic model takes into account: – Clinician’s estimate of prognosis – Laboratory values – Comorbidities – Functional status
  • 55. HD Mortality Predictor Mathematical model for estimating patient survival at 6 months using – The “Surprise” question – Serum albumin – Age – Presence or absence of dementia and PVD http://touchcalc.com/calculators/sq Cohen et al, Clin J Am Soc Nephrol 2010; 5(1):72-9
  • 56.
  • 57.
  • 58. Palliative Care Definition Palliative care is comprehensive, interdisciplinary care of patients and families facing a chronic or terminal illness focusing primarily on comfort and support. Billings JA. Palliative Care. Recent Advances. BMJ 2000:321:555-558.
  • 59. Aspects of Palliative Care Pain and symptom management Advance care planning –DNR –Advance Directives Psychosocial and spiritual support
  • 60. When is Palliative Care Needed? Around the decision to stop dialysis At the onset of conservative management When symptoms from co-morbid conditions are severe At times of crisis e.g. new diagnosis of malignancy, or acute severe symptoms Patients who develop renal failure as a consequence of other life threatening conditions or its treatment e.g. cancer
  • 61. Criteria for Withholding Dialysis Patient or surrogate wishes Profound neurologic impairment – Persistent vegetative state, stroke, dementia Non-renal terminal condition – Malignancy, end-stage liver, heart, lungs Medical condition that precludes process of dialysis Age, per se, is not a criterion to withhold dialysis
  • 62. Symptoms During Last 24 Hours N=79 Symptom % present Pain 42 Agitation 30 Myoclonus/twitching 28 Dyspnea/agonal breathing 25 Fever 20 Diarrhea 14 Dysphagia 14 Nausea 13 Cohen et al. AJKD, 2000;36:140-144
  • 63. RPA/ASN Statement on Quality Care at the End of Life
  • 64. Recommendations 1. All members of the renal health care team including nephrologists, nephrology nurses, nephrology social workers, and renal dietitians should obtain education and skills in the principles of palliative care to ensure that ESRD patients and families receive multidimensional, compassionate, and competent care at the end of life. RPA/ASN Statement on Quality Care at the End of Life
  • 65. RPA/ASN Statement on Quality Care at the End of Life 2. In responding to an ESRD patient/surrogate decision to forgo dialysis, the nephrologist is obligated to determine, if possible, why the patient/surrogate has decided to forgo dialysis … Once the nephrologist is satisfied that the patient’s decision to forgo dialysis is informed and uncoerced, the nephrologist should respect the wishes of the patient/surrogate.
  • 66. 3. After a decision is made to forgo dialysis, the renal team should refer the patient to a hospice or adopt a palliative care approach to patient care. In either case, the nephrologist and other members of the renal team should remain active in the patient’s care to maintain continuity of relationships and treatment. RPA/ASN Statement on Quality Care at the End of Life
  • 67. 4. Nephrologists and other members of the renal team should obtain education and skills in advance care planning so that they are comfortable addressing end-of-life issues with their patients. RPA/ASN Statement on Quality Care at the End of Life
  • 68. Exposure to Palliative Care Geriatrics Critical Care Nephrology Completed a Rotation Focused on Palliative Care 71% 2% 1% Had Contact with Palliative Care Specialist 80% 46% 45% Quality of teaching with respect to end-of-life care rated ‘very good’ or ‘excellent’ 53% 34% 15% Holley et al. Am J Kidney Dis 42(4):813-820, 2003.
  • 69. Amount of Training to Manage a Dying Patient 0% 10% 20% 30% 40% 50% 60% 0-3 4-7 8-10 0=No Training 10=A Lot of Training Geriatrics Pulmonary/ Critical Care Nephrology
  • 70. Clinical Scenario Age 85 eGFR 30 Congestive heart failure, unable to manage stairs No proteinuria
  • 71. Cont’d This patient is likely to have a cardiorenal syndrome Evidence of progression? – if not, conservative management – if so, is there any prospect of reversibility (in this case probably not) or would the patient tolerate/ benefit from renal replacement therapy (in this case probably not) Palliative care pathway
  • 72. Summary Assess risk for CKD progression – Serial eGFR – Proteinuria and other risk factors Assess CV risk – As per high risk group guidelines Assess for CKD complications – Anemia – Bone disease – Malnutrition Assess for renal replacement VS Non-dialytic therapy Assess for palliative care